House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Infectious diseases

Urinary tract infection (recurrent): antimicrobial prescribing

NICE · 2024 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG112 sets out a stepwise approach to preventing recurrent urinary tract infection, with its updated methenamine recommendations alongside vaginal oestrogen and selective antibiotic prophylaxis. Prevention follows adequate treatment of an active infection and assessment of the urinary anatomy, pregnancy status and need for specialist investigation.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Define recurrence and identify specialist pathways

  • In adults, the guideline defines recurrence as at least 2 UTIs in 6 months or at least 3 in 12 months. Recurrent infection may involve the upper or lower tract and may represent relapse with the same strain or reinfection with a different organism. [1]
  • Manage an acute UTI using the appropriate acute lower-UTI or pyelonephritis pathway. Give advice about behavioural measures, personal hygiene and self-care to reduce recurrence. [1]
  • Refer or seek specialist advice for recurrent upper UTI, unexplained recurrent lower UTI, pregnancy, children under 16, suspected cancer, or prior gender reassignment surgery altering the urethra. The same applies from age 16 to men and other people with a male genitourinary system. [1]

Consider vaginal oestrogen for the eligible menopausal population

  • For people with a female urinary system who are experiencing or have experienced perimenopause or menopause, consider vaginal oestrogen when behavioural and hygiene measures alone are ineffective or unsuitable. Consult the linked menopause guidance when there is a personal history of breast cancer. [1]
  • Discuss symptom burden, complication risk, possible benefit for dryness, formulation preference and the very low risk of serious adverse effects. Explain that systemic absorption is minimal. Review vaginal oestrogen within 12 months, or sooner by agreement; do not offer systemic HRT solely to prevent recurrent UTI. [1]

Reserve single-dose antibiotics for an identifiable trigger

  • For non-pregnant people with a female urinary system, consider a single-dose antibiotic trial only after behavioural measures and vaginal oestrogen prove ineffective or unsuitable. Treat any current UTI first and use the dose in relation to an identifiable trigger. [1]
  • Choose trigger prophylaxis using symptom frequency and severity, complication risk, prior cultures and antibiotic exposure, and the person’s preference. Explain administration and adverse effects, arrange review within 6 months, and advise prompt help for acute UTI symptoms. [1]

Use methenamine within its stated eligibility and review schedule

  • Consider methenamine instead of daily antibiotics for recurrent UTI in non-pregnant people with a female urinary system only after the current infection is treated and recurrence has not adequately improved with applicable behavioural measures, vaginal oestrogen or trigger prophylaxis. [1]
  • Seek specialist advice before methenamine prophylaxis during pregnancy, for recurrent upper or complicated lower UTI, for a male genitourinary system, or in children and young people. These populations are not covered by the routine adult eligibility pathway. [1]
  • Avoid urinary alkalinising sachets containing potassium or sodium citrate while taking methenamine because they can reduce its effectiveness. Seek help for acute UTI symptoms; review within 6 months and then every 12 months, or sooner by agreement. [1]
  • For eligible people aged 16 and over, the table lists methenamine hippurate 1 g twice daily. The table identifies prevention of recurrent upper or complicated lower UTI as off-label use, requiring the specialist pathway. [1]

Escalate selectively and reassess continued need

  • For non-pregnant people with a female urinary system, consider daily antibiotics when applicable vaginal oestrogen, trigger prophylaxis or methenamine have not improved recurrence. Treat an active infection first and consider investigations for an underlying cause, preferences and long-term antibiotic risks. [1]
  • During pregnancy or with a male genitourinary system, consider daily prophylaxis only with specialist advice after treatment of an active UTI and ineffective or unsuitable behavioural measures or appropriately used methenamine. [1]
  • In children under 16, specialist assessment should address underlying causes before a trial of daily prophylaxis when simpler options are ineffective or unsuitable. Explain that evidence for preventing recurrence and deterioration of renal scars is uncertain. [1]
  • Explain long-term resistance and adverse-effect risks and the need to seek help for acute infection. Review daily prophylaxis at least every 6 months, assessing benefit and whether to continue, change or stop; stopping requires rapid access to acute UTI treatment. [1]

Apply culture results, safety constraints and realistic self-care advice

  • Use local resistance data and recent cultures where possible, and select a different prophylactic antibiotic if treating an acute UTI. The adult table lists trimethoprim 200 mg with a trigger or 100 mg nightly; it warns of first-trimester teratogenic risk and manufacturer pregnancy contraindication. [1]
  • The adult table lists nitrofurantoin only with eGFR at least 45 ml/minute: 100 mg with a trigger or 50–100 mg nightly. Avoid it at term because of neonatal haemolysis risk and follow pulmonary and hepatic monitoring advice. [1]
  • The guideline describes uncertain benefit from cranberry products and no evidence of benefit in older people with a female urinary system; children considering cranberry need paediatric specialist advice. Account for sugar in cranberry or D-mannose products, and explain that probiotic evidence is inconclusive. [1]

Limitations and use

  • This is prevention guidance, not treatment of acute cystitis, pyelonephritis or sepsis. Adult prophylaxis examples do not replace assessment of renal function, pregnancy, interactions and product-specific precautions. Detailed paediatric dose tables are not reproduced. UK licensing and safety notices are reported in the source’s stated context rather than independently verified for another jurisdiction.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Urinary tract infection (recurrent): antimicrobial prescribing

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
31 October 2018
Publisher’s latest update
12 December 2024
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Define recurrence and identify specialist pathways
  • Consider vaginal oestrogen for the eligible menopausal population
  • Reserve single-dose antibiotics for an identifiable trigger
  • Use methenamine within its stated eligibility and review schedule
  • Escalate selectively and reassess continued need
  • Apply culture results, safety constraints and realistic self-care advice
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House